Skip to main content

Advertisement

ADVERTISEMENT

Volume 18 - Issue 2 - February, 2006

Insights

Commentary
08/01/2008
James B. Hermiller, MD
James B. Hermiller, MD
The percutaneous treatment of bifurcation lesions remains suboptimal. A frequent problem, accounting for 10–20% of coronary lesions undergoing percutaneous coronary intervention (PCI), the bifurcation is plagued by acute technical challenges,...
The percutaneous treatment of bifurcation lesions remains suboptimal. A frequent problem, accounting for 10–20% of coronary lesions undergoing percutaneous coronary intervention (PCI), the bifurcation is plagued by acute technical challenges,...
The percutaneous treatment of...
08/01/2008
Journal of Invasive Cardiology

Feature

Original Contribution
08/01/2008
Silvio Zalc, MD, Pedro A. Lemos, MD, Antonio Esteves, MD, Expedito E. Ribeiro, MD, Pedro Horta, MD, Jose C. Nicolau, MD, Jose A.F. Ramires, MD, Marc Cohen, MD, Eulogio E. Martinez, MD
Silvio Zalc, MD, Pedro A. Lemos, MD, ...
Low-molecular weight heparin (LMWH), especially enoxaparin, and unfractionated heparin (UFH), is recommended in the early medical management of acute coronary syndromes.1,2 Compared to intravenous UFH, subcutaneous LMWH has a more predictable...
Low-molecular weight heparin (LMWH), especially enoxaparin, and unfractionated heparin (UFH), is recommended in the early medical management of acute coronary syndromes.1,2 Compared to intravenous UFH, subcutaneous LMWH has a more predictable...
Low-molecular weight heparin...
08/01/2008
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement